Key result
IV nicardipine reduces mean aortic pressure to 78 mm Hg in coronary disease patients.
Why the study?
The hemodynamic effects of nicardipine on left ventricular function and compliance in patients with coronary heart disease were not fully characterized.
Does intravenous nicardipine improve left ventricular hemodynamics in patients with coronary heart disease?
Does intravenous nicardipine improve left ventricular hemodynamics in patients with coronary heart disease?
Intravenous nicardipine provides potent vasodilator effects and improves left ventricular hemodynamics in both normotensive and hypertensive patients with coronary heart disease.
Answers are grounded in this paper and cite their sources.
Acute aortic pressure reduction seen with nicardipine in coronary disease; leaves open outcome benefits pending randomized trials.
The hemodynamic effects of nicardipine were studied in 10 normotensive patients (nine men, one woman; age 43–70 years, mean 56 years) and five patients with mild to moderate hypertension (four men, one woman; age 46–72 years, mean 62.8 years); in all patients coronary heart disease was confirmed by angiography. Hemodynamic parameters were determined before and after intravenous administration of nicardipine in cumulative doses of 2.5, 7.5, and 12.5 mg for 10 min each. Nicardipine significantly reduced systolic aortic pressure, diastolic aortic pressure, and mean aortic pressure in normotensive patients [ 139 ± 8.7 vs. 114 ± 9.2 mm Hg (p < 0.001), 73 ± 9.1 vs. 56 ± 7.9 mm Hg(p < 0.001), 97 ± 7.8 vs. 78 ±7.9 mm Hg (p < 0.001), respectively] and in hypertensive patients [166 ± 7.4 vs. 128 ± 8.6 mm Hg (p < 0.001), 83 ± 9.4 vs. 56 ± 10.9 mm Hg(p < 0.001), 110 ± 15.5 vs. 78 ± 12.0 mm Hg (p < 0.001), respectively]. Systemic vascular resistance was decreased significantly in hypertensive patients [ 1,363 ± 188 vs. 707 ± 137.7 dyn sec cm−5 (p < 0.001)] and in normotensive patients [1,110 ± 225.3 vs. 682 ± 92.4 dyn sec cm−5 (p < 0.001)]. Heart rate increased from 68 ± 6.8 to 83 ± 11.4 beats/min (p < 0.001) in normotensive patients but the increase from 72 ± 14.7 to 80 ± 14.2 beats/min in hypertensive patients was not significant. Mean pulmonary artery pressure did not change significantly in hypertensive patients and increased slightly in normotensive patients. Pulmonary wedge pressure remained almost constant. Stroke volume index increased in normotensive patients from 50.5 ± 7.4 to 56 ± 3.9 ml/m2 (p < 0.01) and in hypertensive patients from 48 ± 11 to 60 ± 10 ml/m2 (p < 0.06), dp/d/max did not change in hypertensive patients and showed a slight increase in normotensive patients [1,502 ± 226.3 vs. 1,884 ± 402.7 mm Hg/s (p < 0.001)]. Improvement of wall motion abnormalities was observed in five normotensive patients and in two hypertensive patients. The preliminary results of Doppler echocardiographically assessed diastolic function measured in five patients did not show a uniform tendency. Side effects were observed in three patients (angina pectoris in one, headache in two). It is concluded that nicardipine provides potent vasodilator effects and can improve left ventricular function in hypertensive and normotensive patients with coronary heart disease.
No takes yet. Share an insight, caveat, or question.
Engberding et al. (1990) studied Coronary heart disease (n=15). Nicardipine vs. Baseline (before administration) was evaluated on Hemodynamic parameters including aortic pressure and systemic vascular resistance. Intravenous nicardipine reduced mean aortic pressure from baseline in normotensive and hypertensive patients with coronary disease.
Synapse has enriched 10 related papers. Consider them for comparative context: